Quick Answer
A guide to MDS, risk assessment, transfusion and the treatments that can change the course.
Medically reviewed by Dr. Sachita Baniya • NMC 20158 • Kathmandu Neurology Clinic & Cognitive Center
Myelodysplastic syndromes (MDS) are a group of marrow disorders in which blood cells are produced abnormally and die before maturity. The result is low blood counts despite a marrow that may be busy or empty.
How MDS presents
- Anaemia causing fatigue and breathlessness
- Low white cells causing recurrent infections
- Low platelets causing bruising or bleeding
- Sometimes no symptoms, found on a routine blood count
Diagnosis
Diagnosis requires persistent cytopenias with dysplastic features on bone marrow examination. Iron staining, flow cytometry, cytogenetics and molecular testing help classify the disease and exclude other causes. The IPSS-R score estimates prognosis.
Risk-adapted treatment
Lower-risk MDS may be managed with observation, growth factors, transfusion and lenalidomide in selected del(5q) cases. Higher-risk MDS may receive hypomethylating agents and be considered for allogeneic transplant.
Transfusion and iron overload
Repeated transfusions can cause iron overload, which may damage the heart, liver and endocrine organs. Iron studies and, in selected patients, chelation are part of long-term care.
Can MDS become leukemia?
Yes, in a proportion of patients. Risk depends on blasts, cytogenetics and molecular findings. Regular monitoring helps detect progression.
Questions to ask
- What is my IPSS-R risk group?
- Do I need treatment now or can we monitor?
- Will I need transfusions, and how often?
- Am I a candidate for transplant?
- What symptoms should prompt urgent review?
The bottom line
MDS is a chronic marrow disorder for many patients. Accurate diagnosis and risk assessment allow treatment to be matched to the disease and the person.
Frequently asked questions
Answers reviewed by Dr. Jitendra Prasad Yadav • MBBS, MD (Internal Medicine), FICN (Neurology), FCNV, FIHM • NMC 8029
No. Some patients remain stable for years, while others progress. Risk depends on marrow blasts, cytogenetics, molecular findings and blood counts.
The Revised International Prognostic Scoring System estimates survival and progression risk using blasts, cytogenetics and cytopenias. It guides treatment intensity.
AML can be cured in a proportion of patients, particularly younger adults who achieve remission and proceed to appropriate consolidation or transplant. Outcomes vary widely with genetic subtype, age and fitness, so the treating team discusses prognosis for the individual case rather than giving a single figure.
Induction is the first phase of treatment, aiming to clear leukemia cells from the marrow and restore normal blood production. It usually requires hospital admission and close support with transfusion, infection prevention and monitoring.
More: All FAQs → · Ask Dr. Jitendra →
Related articles
AML Diagnosis Explained: From Blood Count to Genetic Risk
How acute myeloid leukemia is diagnosed, why bone marrow and genetic testing matter, and what the results mean for treatment.
Bone Marrow Transplant: Autologous, Allogeneic and Haplo-Identical
What a bone marrow transplant involves, who it is for, and the difference between autologous, allogeneic and haplo-identical approaches.
Anaemia: Why the Cause Matters More Than the Number
Anaemia is a sign, not a diagnosis. Learn how the cause is investigated and why iron tablets alone can be insufficient.
Medical Disclaimer
Content on this website is for general educational purposes only and does not constitute medical advice, diagnosis, or treatment. It is not a substitute for evaluation by a qualified healthcare professional. Always seek the advice of your physician or other qualified provider with any questions regarding a medical condition. Never disregard professional medical advice or delay seeking it because of something you have read on this website. In case of a medical emergency, contact emergency services immediately. No doctor–patient relationship is established by use of this site or by contacting the clinic through the site.
References & Review
Reviewed by Dr. Jitendra Prasad Yadav • Last reviewed: 2026-11-10
- International Classification of Headache Disorders, 3rd edition (ICHD-3).
- Harrison's Principles of Internal Medicine — Neurology sections.
- American Academy of Neurology guidelines for selected conditions (where applicable).
Content is educational and aligns with standard medical references; individual evaluation may vary. External links provide context and do not imply endorsement.